1014 related articles for article (PubMed ID: 35813279)
1. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
[TBL] [Abstract][Full Text] [Related]
4. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study.
Stirrup O; Shrotri M; Adams NL; Krutikov M; Azmi B; Monakhov I; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Age Ageing; 2023 Aug; 52(8):. PubMed ID: 37595069
[TBL] [Abstract][Full Text] [Related]
6. Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI).
Stirrup O; Shrotri M; Adams NL; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Open Forum Infect Dis; 2023 Jan; 10(1):ofac694. PubMed ID: 36713473
[TBL] [Abstract][Full Text] [Related]
7. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study.
Tut G; Lancaster T; Sylla P; Butler MS; Kaur N; Spalkova E; Bentley C; Amin U; Jadir A; Hulme S; Ayodele M; Bone D; Tut E; Bruton R; Krutikov M; Giddings R; Shrotri M; Azmi B; Fuller C; Baynton V; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2022 Jul; 3(7):e461-e469. PubMed ID: 35813280
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.
Krutikov M; Palmer T; Tut G; Fuller C; Azmi B; Giddings R; Shrotri M; Kaur N; Sylla P; Lancaster T; Irwin-Singer A; Hayward A; Moss P; Copas A; Shallcross L
Lancet Healthy Longev; 2022 Jan; 3(1):e13-e21. PubMed ID: 34935001
[TBL] [Abstract][Full Text] [Related]
9. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
[TBL] [Abstract][Full Text] [Related]
11. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study.
Piernas C; Patone M; Astbury NM; Gao M; Sheikh A; Khunti K; Shankar-Hari M; Dixon S; Coupland C; Aveyard P; Hippisley-Cox J; Jebb SA
Lancet Diabetes Endocrinol; 2022 Aug; 10(8):571-580. PubMed ID: 35780805
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
Hall VJ; Foulkes S; Saei A; Andrews N; Oguti B; Charlett A; Wellington E; Stowe J; Gillson N; Atti A; Islam J; Karagiannis I; Munro K; Khawam J; Chand MA; Brown CS; Ramsay M; Lopez-Bernal J; Hopkins S;
Lancet; 2021 May; 397(10286):1725-1735. PubMed ID: 33901423
[TBL] [Abstract][Full Text] [Related]
13. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
Agrawal U; Bedston S; McCowan C; Oke J; Patterson L; Robertson C; Akbari A; Azcoaga-Lorenzo A; Bradley DT; Fagbamigbe AF; Grange Z; Hall ECR; Joy M; Katikireddi SV; Kerr S; Ritchie L; Murphy S; Owen RK; Rudan I; Shah SA; Simpson CR; Torabi F; Tsang RSM; de Lusignan S; Lyons RA; O'Reilly D; Sheikh A
Lancet; 2022 Oct; 400(10360):1305-1320. PubMed ID: 36244382
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
15. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J
Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
Tang F; Hammel IS; Andrew MK; Ruiz JG
Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
19. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC
BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698
[TBL] [Abstract][Full Text] [Related]
20. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
